Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
Study of Tisotumab Vedotin (Investigational Drug) in Patients with Ovarian Cancer
Sponsor:Seattle Genetics, Inc.
Enrolling:Female Patients Only
IRB Number:AAAS1622
U.S. Government ID:NCT03657043
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information:

We are doing this study to find out if tisotumab vedotin treats ovarian cancer. We want to see if patients with your kind of ovarian cancer respond to the drug. We want to see how long it takes patients to respond to tisotumab vedotin and how long the response lasts. We also want to learn more about any side effects patients have when they get tisotumab vedotin.Tisotumab vedotin is a type of drug called an antibody drug conjugate or ADC. ADCs usually have 2 parts. Antibody: Antibodies are part of your immune system. Usually, they help protect you from getting sick. In tisotumab vedotin, we are using an antibody that is designed to find and stick to the ovarian cancer cells in your body. Drug: the part of the ADC that kills cells. The cell-killing part of tisotumab vedotin is a drug called MMAE. In tisotumab vedotin, the antibody part is designed to stick to cancer cells so that the drug part can killthem. It may also stick to some non-cancer cells in your body.

Do You Qualify?
Have you been diagnosed with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Reena Vattakalam
Email: rmv2110@cumc.columbia.edu
Phone: 212-342-6895